Main Menu

Dr Anderson Wang

Team Leader

The alt text
Dr Anderson Wang will apply his research expertise in DNA repair and industry experience to support the drug development programmes, as he leads the Target Biology and Genomic Instability Team at the ICR. Team: Target Biology and Genomic Instability

Dr Anderson Wang has gained research training in cancer biology and therapeutics in both academic and industry settings.

He received his BSc (Hons) in biomedical sciences with specialisation in cancer biology and therapeutics from the University of Auckland. He was then awarded the Top Achiever Doctoral Scholarship from the New Zealand government for his DPhil study in medical oncology at the University of Oxford. During his doctoral research, he employed molecular and cell biology approaches to elucidate the roles of DNA repair factors in preventing genomic instability.

He continued to research DNA repair in a clinical context during his postdoctoral training at the Rockefeller University. From this work, he discovered a novel function of RAD51 protein in replication fork protection by studying a separation-of-function mutation identified in Fanconi anemia patients. In 2013, he was awarded the US Department of Defense postdoctoral research training fellowship.

He joined AstraZeneca as a senior scientist in 2015 to gain industry experience in drug discovery and development. He applied his scientific training in DNA repair to support the drug development programmes of DNA damage response inhibitors. He was then promoted to the Associate Principal Scientist position and led projects at both early and late stages of drug development. Throughout his time at AstraZeneca, he has contributed to elucidating the mechanisms of action and biomarker discovery.

At The Institute of Cancer Research, Dr Wang will apply his research expertise in DNA repair and industry experience to support the drug development programmes within the Cancer Research UK Cancer Therapeutics Unit.